Nonmetastatic CRPC: Considerations for Apalutamide

(4:36)

Ep. 6: Identifying Nonmetastatic CRPC

(6:50)

Understanding Nonmetastatic CRPC: An Overview

(6:51)

When to Treat Nonmetastatic CRPC

(3:8)

An Update on the PROSPER Trial: Focusing on Nonmetastatic CRPC

(21:25)

Apalutamide in Treating Nonmetastatic CRPC

(5:20)

Dr. Choudhury on Antiandrogen Treatment Selection in Nonmetastatic CRPC

(1:45)

AUA Guidelines on Advanced/Metastatic/Castration Resistant Prostate Cancer Webcast (2021)

(1:52:45)

Case 1: The Importance of PSA Doubling Time in Prostate Cancer

(5:15)

What is Nubeqa for Prostate Cancer and How Does it Work? | Ask a Prostate Expert, Mark Scholz, MD

(6:46)

Metastatic #ProstateCancer Treatment Case Study | #MarkScholzMD #AlexScholz #PCRI

(13:52)

Cystic Fibrosis: From Gene Discovery to Basic Biology to Precision Medicines

(4:19:21)

AUA2024: AUA Advanced Prostate Cancer Guidelines

(2:5:8)

The 3-Minute Neck Sequence That Will Change Your Life

(9:8)

Apalutamide for High-Risk Prostate Cancer | Learn About Clinical Trials

(4:23)

ProsTIC24 - Aravind Ravi Kumar: \

(8:34)

Metastatic castration resistant prostate cancer: Updates from ASCO 2019

(23:3)

The Future of Treatment for Nonmetastatic CRPC

(5:55)

Nonmetastatic CRPC: meeting an unmet need

(1:19)

Dr. Lee on Choosing Among Antiandrogens in Nonmetastatic CRPC

(55)

Apalutamide: A Next-Gen Agent for Nonmetastatic CRPC

(4:53)

Dr. Gomella on the FDA Approval of Apalutamide for Nonmetastatic CRPC

(1:10)

Darolutamide’s Role in Treating Nonmetastatic CRPC

(4:41)

Nonmetastatic CRPC: MFS and AR-Targeted Agents

(3:3)

Nonmetastatic CRPC: Initial Diagnostic Workup

(3:44)

Dr. Choudhury on Treatment Goals in Nonmetastatic CRPC

(1:4)

The Rationale for ARN-509 in Nonmetastatic CRPC

(3:21)

Dr. Gomella on the FDA Approval of Enzalutamide in Nonmetastatic CRPC

(51)

Approaching the Treatment of Nonmetastatic CRPC

(6:3)

Nonmetastatic CRPC: The Changing Landscape of Treatment

(4:32)